Company Analysis
Sign in

BioNTech SE (BNTX)

Nasdaq: BNTX · Biological Products, (No Diagnostic Substances) · Mainz, DE · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.9
◀ Past 6.8● Present 5.8▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€2.87B+4.3%
Net income-€1.14B-70.8%
Earnings per share€-4.70-69.7%
Operating cash flow€456M+119.5%
Cash€7.68B-21.4%
Debtn/a
Shareholders’ equity€19.22B-1.0%
Shares, diluted241.7M+0.5%
Return on equity-5.9%
The recordfrom its filings
Filings in 202678
Newest filingNov 10 · 6-K
Annual reportMar 10, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$89.8M
Insider buys, 12 months$0.00
Patents granted301
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in EUR. Nothing here is a forecast.

News

Oct 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BNTX · research, not advice